Novartis AG $NVS Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC increased its position in shares of Novartis AG (NYSE:NVS - Free Report) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,121,414 shares of the company's stock after purchasing an additional 358,282 shares during the period. Fisher Asset Management LLC owned 0.34% of Novartis worth $861,762,000 at the end of the most recent quarter.

• Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after acquiring an additional 2,666 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Novartis by 8.6% during the 1st quarter. TD Asset Management Inc now owns 17,429 shares of the company's stock worth $1,943,000 after buying an additional 1,374 shares during the last quarter. Commerce Bank boosted its holdings in shares of Novartis by 12.2% in the 1st quarter. Commerce Bank now owns 23,813 shares of the company's stock valued at $2,655,000 after buying an additional 2,581 shares in the last quarter. TIAA Trust National Association boosted its holdings in shares of Novartis by 7.6% in the 1st quarter. TIAA Trust National Association now owns 8,474 shares of the company's stock valued at $945,000 after buying an additional 599 shares in the last quarter. Finally, IFG Advisory LLC grew its position in shares of Novartis by 427.6% in the 1st quarter. IFG Advisory LLC now owns 12,869 shares of the company's stock valued at $1,435,000 after buying an additional 10,430 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NVS shares. Cowen restated a "hold" rating on shares of Novartis in a research note on Monday, November 10th. Jefferies Financial Group restated a "hold" rating on shares of Novartis in a research note on Monday, October 27th. Morgan Stanley raised Novartis from an "equal weight" rating to an "overweight" rating in a research report on Friday, October 31st. Cfra Research raised Novartis to a "hold" rating in a report on Wednesday, October 29th. Finally, Weiss Ratings restated a "buy (b)" rating on shares of Novartis in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $122.33.

• 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

Get Our Latest Research Report on NVS

Novartis Trading Down 0.2%

Shares of NVS stock opened at $130.23 on Monday. The company has a market capitalization of $275.09 billion, a P/E ratio of 17.79, a price-to-earnings-growth ratio of 1.93 and a beta of 0.60. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.50. The business's 50 day moving average is $128.31 and its two-hundred day moving average is $122.74. Novartis AG has a twelve month low of $96.06 and a twelve month high of $134.00.

• 3 Momentum Stocks That Could Soar Post-Market Volatility

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing the consensus estimate of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The company had revenue of $14.36 billion for the quarter, compared to analyst estimates of $13.70 billion. During the same period in the prior year, the business earned $2.06 earnings per share. Novartis's revenue for the quarter was up 8.5% compared to the same quarter last year. Equities analysts forecast that Novartis AG will post 8.45 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

See Also

• Five stocks we like better than Novartis
• What is diluted earnings per share (Diluted EPS)?
• Worried About Inflation? These 3 ETFs Offer Real Protection
• Using the MarketBeat Dividend Tax Calculator
• Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally
• Dividend Screener: How to Evaluate Dividend Stocks Before Buying
• Klarna's Crypto Play: A Plan to Fix Its Profit Problem

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novartis Right Now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here